GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Other Gross PPE

Dynavax Technologies (FRA:DYF1) Other Gross PPE : €55.0 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Other Gross PPE?

Dynavax Technologies's Other Gross PPE for the quarter that ended in Mar. 2024 was €55.0 Mil.

Dynavax Technologies's quarterly Other Gross PPE increased from Sep. 2023 (€57.3 Mil) to Dec. 2023 (€73.4 Mil) but then declined from Dec. 2023 (€73.4 Mil) to Mar. 2024 (€55.0 Mil).

Dynavax Technologies's annual Other Gross PPE increased from Dec. 2021 (€60.7 Mil) to Dec. 2022 (€68.0 Mil) and increased from Dec. 2022 (€68.0 Mil) to Dec. 2023 (€73.4 Mil).


Dynavax Technologies Other Gross PPE Historical Data

The historical data trend for Dynavax Technologies's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Other Gross PPE Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.08 59.00 60.73 68.03 73.42

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.40 57.97 57.28 73.42 55.02

Dynavax Technologies Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Dynavax Technologies (FRA:DYF1) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines